AstraZeneca – A biopharmaceutical Company
In a significant development, AstraZeneca has officially recognized a rare but serious side effect associated with its widely administered COVID-19 vaccine, Covishield. This news delves into the details of this acknowledgment and what it means for vaccine recipients.
What is Thrombosis with Thrombocytopenia Syndrome (TTS)?
Thrombosis with Thrombocytopenia Syndrome (TTS) is a condition characterized by the formation of blood clots in combination with a low platelet count. Though the condition is exceptionally rare, it has been observed in a minute fraction of individuals following vaccination with Covishield.
AstraZeneca Acknowledgment
Recent court documents have revealed that AstraZeneca has admitted to the occurrence of TTS in a small number of vaccine recipients. The company has extended its sympathies to those affected and is actively working with health authorities to ensure patient safety.
The Numbers Behind the News
The incidence rate of TTS post-vaccination is reported to be around one in 50,000, or 0.002%. While this percentage is minuscule, it becomes a matter of concern when scaled to a population level, especially in densely populated countries.
Balancing Risks and Benefits
Despite the identification of this side effect, health experts and regulatory bodies maintain that the benefits of receiving the Covishield vaccine far outweigh the risks. Vaccination remains a critical tool in the fight against COVID-19, and the risk of severe disease without vaccination is significantly higher.
AstraZeneca’s transparency is a step forward in understanding the complexities of vaccine side effects. It is crucial for individuals to stay informed and consult healthcare professionals for advice tailored to their personal health circumstances.
Disclaimer: The information provided in this guide is for informational purposes only and does not constitute legal or financial advice
For Media Enquiries/Guest Posting/Press Release – Write for us
